effectiveness and side effects of Spinaraza and Risidiplam on the motor performance of patients with spinal muscular atrophy
Not Applicable
Recruiting
- Conditions
- Spinal Muscular Atrophy.Spinal muscular atrophy and related syndromes
- Registration Number
- IRCT20120821010634N4
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
SMA clinical diagnosis by pediatric neurologist
SMA diagnosis according to genetic test
Exclusion Criteria
The patient do not have a consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of Motor Function. Timepoint: one month, 3 months, and 6 months after drug initiation. Method of measurement: Assessment of motor function based on Hammersmith and HINE scales.;Clinical and laboratory side effects of drugs. Timepoint: one month, 3 months, and 6 month after drug initiation. Method of measurement: fulfilling check list according to patient reports, requesting CBC, liver and renal function tests.
- Secondary Outcome Measures
Name Time Method